Review: Immune cells and mediators of inflammatory arthritis

Autoimmunity

Volumn 41, Issue 3, 2008, Pages 224-229

  Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bone erosion; Osteoclasts; RANKL; Synovitis

Indexed keywords

ADALIMUMAB; ATLIZUMAB; C REACTIVE PROTEIN; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; BONE DEVELOPMENT; BONE EROSION; CELL DIFFERENTIATION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE REMODELING; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOCLASTS; RANK LIGAND; SYNOVIAL MEMBRANE; SYNOVITIS; TUMOR NECROSIS FACTORS;

EID: 41449106186     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930701694717     Document Type: Article

References (47)

1. Schett, G., Kiechl, S., Weger, S., Mayr, A. and Oberhollenzer, S. (2006) High-sensitivity C-reactive protein and risk of non-traumatic fractures in the Bruneck Study. Arch Intern Med, 166, pp. 2495-2501.
2. Firestein, GS (2003) Evolving concepts of rheumatoid arthritis. Nature, 423, pp. 356-361.
3. Mil, AH van der Helm-van, Wesoly, JZ and Huizinga, TW (2005) Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol, 17, pp. 299-304.
4. Klareskog, L., Padyukov, L. and Alfredsson, L. (2007) Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol, 19, pp. 49-54.
5. Scott, DL, Pugner, K., Kaarela, K., Doyle, DV, Woolf, A. and Holmes, J. (2000) The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford), 39, pp. 122-132.
6. Pincus, T. (1988) Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol, 41, pp. 1037-1041.
7. Welsing, PM, van Gestel, AM, Swinkels, HL, Kiemeney, LA and van Riel, PL (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum, 44, pp. 2009-2017.
8. Aletaha, D., Smolen, J. and Ward, MM (2006) Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum, 54, pp. 2784-2792.
9. McInnes, I. and Schett, G. (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Immunol, 7, pp. 429-442.
10. Gravallese, EM, Harada, Y., Wang, JT, Gorn, AH, Thornhill, TS and Goldring, SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol, 152, pp. 943-951.
11. Weichselbaum, A. Die feineren Veränderungen des Gelenkknorpels bei fungöser Synovitis und Karies der Gelenkenden. Archiv Pathol Anat Physiol Klin Med, 73, pp. 461-475.
12. Bromley, M. and Woolley, DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum, 27, pp. 968-975.
13. Schett, G., Stolina, M., Bolon, B., Middleton, S., Adlam, M., Brown, H., Zhu, L., Feige, U. and Zack, DJ (2005) Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum, 52, pp. 3192-3201.
14. Hayer, S., Redlich, K., Korb, A., Hermann, S., Smolen, J. and Schett, G. (2006) Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum, 56, pp. 79-88.
15. Van der Heijde, DM (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol, 34, pp. 74-78.
16. Machold, KP, Stamm, TA, Nell, VP, Pflugbeil, S., Aletaha, D., Steiner, G., Uffmann, M. and Smolen, JS (2007) Very recent onset rheumatoid arthritis: Clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford), 46, pp. 342-349.
17. Redlich, K., Hayer, S., Ricci, R., David, JP, Tohidast-Akrad, M. and Kollias, G. (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest, 110, pp. 1419-1427.
18. Teitelbaum, SL (2000) Bone resorption by osteoclasts. Science, 289, pp. 1504-1508.
19. Li, P., Schwarz, EM, O'Keefe, MaL, Boyce, BF and Xing, L. (2004) RANK signaling is not required for TNF-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res, 19, pp. 207-213.
20. Seitz, M., Loetscher, P., Fey, MF and Tobler, A. (1994) Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol, 33, pp. 613-619.
21. Shigeyama, Y., Pap, T., Kunzler, P., Simmen, BR, Gay, RE and Gay, S. (2000) Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum, 43, pp. 2523-2530.
22. Gravallese, EM, Manning, C., Tsay, A., Naito, A., Pan, C. and Amento, E. (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum, 43, pp. 250-258.
23. Yoshida, H. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature, 345, pp. 442-444.
24. Lacey, DL, Timms, E., Tan, HL, Kelley, MJ, Dunstan, CR and Burgess, T. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, pp. 165-176.
25. Dougall, WC, Glaccum, M. and Charrier, K. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev, 13, pp. 2412-2424.
26. Simonet, WS, Lacey, DL, Dunstan, CR, Kelley, M., Chang, MS and Luthy, R. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89, pp. 309-319.
27. Pettit, AR, Ji, H., von Stechow, D., Müller, R., Goldring, SR and Choi, Y. (2001) TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol, 159, pp. 1689-1699.
28. Kong, YY, Feige, U., Sarosi, I., Bolon, B., Tafuri, A. and Morony, S. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402, pp. 304-309.
29. Redlich, K., Hayer, S., Maier, A., Dunstan, CR, Tohidast, AM and Lang, S. (2002) Tumor necrosis factor a - mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum, 46, pp. 785-792.
30. Romas, E., Gillespie, MT and Martin, TJ (2002) Involvement of receptor activator of NFkB ligand and tumor necrosis factor - a in bone destruction in rheumatoid arthritis. Bone, 30, pp. 340-346.
31. Lubberts, E., Bersselaar, L van den, Oppers-Walgreen, B., Schwarzenberger, P., Roo, CJ Coenen-de, Kolls, JK, Joosten, LA and Berg, WB van den (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/ osteoprotegerin balance. J Immunol, 170, pp. 2655-2662.
32. Diarra, D., Stolina, M., Polzer, K., Zwerina, J., Ominsky, MS, Dwyer, D., Korb, A., Smolen, J., Hoffmann, M., Scheinecker, C., van der Heide, D., Landewe, R., Lacey, D., Richards, WG and Schett, G. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med, 13, pp. 156-163.
33. Bathon, JM, Martin, RW, Fleischmann, RM, Tesser, JR, Schiff, MH, Keystone, EC, Genovese, MC, Wasko, MC, Moreland, LW, Weaver, AL, Markenson, J. and Finck, BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med, 343, pp. 1586-1593.
34. Lipsky, PE, van der Heijde, DM, Clair, EW St., Furst, DE, Breedveld, FC, Kalden, JR, Smolen, JS, Weisman, M., Emery, P., Feldmann, M., Harriman, GR and Maini, RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med, 343, pp. 1594-1602.
35. Keystone, EC, Kavanaugh, AF, Sharp, JT, Tannenbaum, H., Hua, Y., Teoh, LS, Fischkoff, SA and Chartash, EK (2004) Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized placebo-controlled 52-week trial. Arthritis Rheum, 50, pp. 1400-1411.
36. Ritchlin, CT (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest, 111, pp. 821-831.
37. Lam, J., Takeshita, S., Barker, JE, Kanagawa, O., Ross, FP and Teitelbaum, SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest, 106, pp. 1481-1488.
38. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E. and Kioussis, D. (1991) Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J, 10, pp. 4025-4031.
39. Zwerina, J., Tzima, S., Hayer, S., Redlich, K., Hoffmann, O., Hanslik-Schnabel, B., Smolen, JS, Kollias, G. and Schett, G. (2005) Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. FASEB J., 19, pp. 2011-2013.
40. Wei, S., Kitaura, H., Zhou, P., Ross, FP and Teitelbaum, SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest, 115, pp. 282-290.
41. Maini, RN, Taylor, PC, Szechinski, J., Pavelka, K., Broll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., Thomson, D., Kishimoto, T. and CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum, 54, pp. 2817-2829.
42. Wong, PK (2006) Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum, 54, pp. 158-168.
43. Takayanagi, H. (2000) HT-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma. Nature, 408, pp. 600-605.
44. Udagawa, N. (1997) Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med, 185, pp. 1005-1012.
45. Sato, K. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203, pp. 2673-2682.
46. McClung, MR, Lewiecki, EM, Cohen, SB, Bolognese, MA, Woodson, GC, Moffett, AH, Peacock, M., Miller, PD, Lederman, SN, Chesnut, CH, Lain, D., Kivitz, AJ, Holloway, DL, Zhang, C., Peterson, MC and Bekker, PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 354, pp. 821-831.
47. Conaghan, PG, Sloan, VS, Papanstasiou, P., Ortmann, CE, O'Connor, PJ, Grainger, AJ and Emery, P. (2004) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum, 50, pp. 265-276.